DE60217904D1 - Verwendung von quinazolinen zur behandlung von t-zell vermittelten krankheiten - Google Patents

Verwendung von quinazolinen zur behandlung von t-zell vermittelten krankheiten

Info

Publication number
DE60217904D1
DE60217904D1 DE60217904T DE60217904T DE60217904D1 DE 60217904 D1 DE60217904 D1 DE 60217904D1 DE 60217904 T DE60217904 T DE 60217904T DE 60217904 T DE60217904 T DE 60217904T DE 60217904 D1 DE60217904 D1 DE 60217904D1
Authority
DE
Germany
Prior art keywords
sub
treatment
cell mediated
mediated diseases
quinazolines
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60217904T
Other languages
English (en)
Other versions
DE60217904T2 (de
Inventor
Corine Moore
Keith Oldham
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of DE60217904D1 publication Critical patent/DE60217904D1/de
Application granted granted Critical
Publication of DE60217904T2 publication Critical patent/DE60217904T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE60217904T 2001-11-23 2002-11-20 Verwendung von quinazolinen zur behandlung von t-zell vermittelten krankheiten Expired - Fee Related DE60217904T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0128109.6A GB0128109D0 (en) 2001-11-23 2001-11-23 Therapeutic use
GB0128109 2001-11-23
PCT/GB2002/005217 WO2003045364A2 (en) 2001-11-23 2002-11-20 Use of quinazolines to treat t-cell mediated diseases

Publications (2)

Publication Number Publication Date
DE60217904D1 true DE60217904D1 (de) 2007-03-15
DE60217904T2 DE60217904T2 (de) 2007-11-15

Family

ID=9926330

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60217904T Expired - Fee Related DE60217904T2 (de) 2001-11-23 2002-11-20 Verwendung von quinazolinen zur behandlung von t-zell vermittelten krankheiten

Country Status (7)

Country Link
US (1) US7157467B2 (de)
EP (1) EP1453492B1 (de)
AT (1) ATE352295T1 (de)
AU (1) AU2002339194A1 (de)
DE (1) DE60217904T2 (de)
GB (1) GB0128109D0 (de)
WO (1) WO2003045364A2 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1330444B1 (de) 2000-11-01 2011-03-23 Millennium Pharmaceuticals, Inc. Stickstoffhaltige heterozyklische verbindungen und verfahren zu deren herstellung
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
DE60327323D1 (de) * 2002-07-09 2009-06-04 Astrazeneca Ab Chinazoline derivative und ihre anwendung in der krebsbehandlung
GB0317665D0 (en) 2003-07-29 2003-09-03 Astrazeneca Ab Qinazoline derivatives
EP1921070A1 (de) 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
CA2677336A1 (en) 2007-02-06 2008-08-14 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, pharmaceutical compositions containing these compounds, the use thereof and processes for the preparation thereof
KR20100111291A (ko) 2008-02-07 2010-10-14 베링거 인겔하임 인터내셔날 게엠베하 스피로사이클릭 헤테로사이클, 상기 화합물을 함유하는 약제, 이의 용도 및 이의 제조 방법
CN102088979B (zh) 2008-05-13 2013-10-16 阿斯利康(瑞典)有限公司 4-(3-氯-2-氟苯胺基)-7-甲氧基-6-{[1-(n-甲基氨基甲酰基甲基)哌啶-4-基]氧基}喹唑啉的富马酸盐
CA2733153C (en) 2008-08-08 2016-11-08 Boehringer Ingelheim International Gmbh Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6046206A (en) * 1995-06-07 2000-04-04 Cell Pathways, Inc. Method of treating a patient having a precancerous lesions with amide quinazoline derivatives
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
JPH11209350A (ja) * 1998-01-26 1999-08-03 Eisai Co Ltd 含窒素複素環誘導体およびその医薬
DK1553097T3 (da) 1999-02-10 2010-12-13 Astrazeneca Ab Quinazolinderivat som angiogeneseinhibitor og mellemprodukter dertil
PL202812B1 (pl) 2000-08-21 2009-07-31 Astrazeneca Ab Pochodna chinazoliny, jej kompozycja famaceutyczna oraz jej zastosowanie

Also Published As

Publication number Publication date
US7157467B2 (en) 2007-01-02
WO2003045364A3 (en) 2003-08-28
EP1453492A2 (de) 2004-09-08
EP1453492B1 (de) 2007-01-24
AU2002339194A8 (en) 2003-06-10
WO2003045364A2 (en) 2003-06-05
AU2002339194A1 (en) 2003-06-10
ATE352295T1 (de) 2007-02-15
US20050014773A1 (en) 2005-01-20
GB0128109D0 (en) 2002-01-16
DE60217904T2 (de) 2007-11-15

Similar Documents

Publication Publication Date Title
EP1450808B8 (de) Quinazolinderivate für die behandlung durch t-zellen vermittelter krankheiten
GB0226931D0 (en) Chemical compounds
CY1107539T1 (el) Παραγωγα κουιναζολινης
DE60219793D1 (de) Methode zur behandlung von zytokinvermittelten erkrankungen
DE69823344D1 (de) Substituierte benzimidazol-derivaten und ihre verwendung zur behandlung retroviraler infektionen
TR200102967T2 (tr) Substitüsyonlu azollar
ATE414089T1 (de) Verwendung von rapamycin und dessen derivaten zur behandlung von knochenverlust
DE60204548D1 (de) Mch antagonisten und deren verwendung zur behandlung von fettleibigkeit
LT2001004A (en) Fertilizer from sapropel and manufacture thereof
DE60133921D1 (de) Verwendung von rosuvastatin (zd-4522) zur behandlung von heterozygoter familiärer hypercholesterolämie
ATE354563T1 (de) Sulfonderivate zur hemmung von gamma-secretase
YU21401A (sh) Tetrahidropiridoetri
NO20011283D0 (no) Anvendelse av integrin-antagonister ved behandling av multippelt myelom og myelom-indusert benresorpsjon
DE60217904D1 (de) Verwendung von quinazolinen zur behandlung von t-zell vermittelten krankheiten
DE602004005814D1 (de) Verfahren zur behandlung von übelkeit, erbrechen, würgereiz oder jede kombination daraus
NO20020042D0 (no) Kinazolinderivater
ATE442854T1 (de) Verwendung von 5'-methylthioadenosin zur prävention und/oder behandlung von autoimmunkrankheiten und/oder transplantatabstossung
ATE369348T1 (de) Zyklisierte benzamid-neurokinin-antagonisten zur verwendung in therapie
ATE148109T1 (de) Hiv-proteaseinhibitoren und ihre verwendung zur behandlung von aids
ATE290857T1 (de) Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen
ATE413394T1 (de) Guanidin-derivate von chinazoin zur behandlung von autoimmunkrankheiten
ZA979338B (en) Peptide compounds.
PL363467A1 (en) Denitrification of aquarium water
ATE314066T1 (de) Verwendung von buprenorphin zur therapie der harninkontinenz
DE50207119D1 (de) 4-(benzyliden-amino)-3-(methylsulfanyl) -4h-(1, 2, 4) triazin-5-on derivate mit pde -iv hemmender und tnf-antagonistischer wirkung zur behandlung von herzkrankheiten und allergien

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee